In the present trial, we compared the broncholytic efficacy of the combination therapy with 50
μg salmeterol+ 250 μg fluticasone and 12 μg formoterol+ 400 μg budesonide, both in a …

Formoterol is a β2-agonist bronchodilator that combines a fast onset of action with a long
duration of broncholytic effect. An increasing documentation is showing that the combination …

In the present study, we examined whether there is a difference in the onset of
bronchodilatation between formoterol/beclomethasone 12/200 μg Modulite and …

Formoterol fumarate is a β2-agonist bronchodilator that combines a fast onset of action with
a long duration of action. Its fast onset of action is well documented in asthma but has not …

OBJECTIVES: To compare the onset and magnitude of bronchodilation after dry powder
inhalations of formoterol fumarate (Foradil Aerolizer) versus salmeterol xinofoate (Serevent …

We studied 16 patients with stable COPD in a double blind, double dummy, placebo-
controlled, within patient study to see if formoterol could be used as a rescue drug. We …

BACKGROUND: Chronic obstructive pulmonary disease (COPD) patients are thought to
have limited bronchodilator response, determined by changes in forced expiratory volume in …

Background: This is the first comparison of two combination therapies, fluticasone
propionate/salmeterol and ipratropium bromide/albuterol (salbutamol), for the treatment of …

Background: β 2-Agonists andcorticosteroids or theophylline can interact to produce
beneficialeffects on airway function in asthma, but this has not been establishedin COPD …

The effects of the long-acting β2-agonist formoterol, the anticholinergic drug oxitropium
bromide, and their combination were compared in 16 patients with partially reversible stable …